Web Content Viewer

$$ Stephen Xavier Skapek, MD Division Director at Children's Health Professor at UT Southwestern Medical Center

Share:
Share:

UTSW Physician Practicing at Children's Health

Appointments: 214-456-2978


Locations
Board Certification American Board of Pediatrics/Hematology-Oncology
Languages Spoken: English
Share:
Biography

Biography

Stephen Skapek, M.D., is the medical director of the Gill Center for Cancer and Blood Disorders at Children’s Health℠ and chief of the Division of Pediatric Hematology/Oncology at UT Southwestern Medical Center.

“I serve as an attending physician, caring for children who have cancer or blood disease admitted to the Children’s Health Dallas and Children’s Health Plano hospitals,” Dr. Skapek explained. “I also devote a substantial amount of time leading a laboratory research program at UT Southwestern; my laboratory research is focused on understanding the drivers of childhood cancer and trying to turn that understanding into better treatments for children with cancer. Finally, as the chief of the Division of Hematology/Oncology and medical director of the Gill Center at Children’s, I oversee all aspects of our clinical practice as well as our educational and research programs in childhood cancer and blood disease. Though it seems, at times, to be a big job, my main priority is to be certain that we are providing the very best care to the children we serve.”

After earning his medical degree from Duke University in Durham, N.C., Dr. Skapek completed his pediatrics residency at Wilford Hall Medical Center at Lackland Air Force Base in San Antonio and fellowship training in pediatric hematology/oncology at Dana-Farber Cancer Institute and Boston Children’s Hospital, both of which are teaching affiliates of Harvard Medical School.

Research appealed to Dr. Skapek because of his interest in disease biology and the potential to develop new and better cancer treatments. “In medical school, I had to decide between medical oncology, surgical oncology and pediatric oncology,” he said. “I felt that caring for children with cancer and blood disease brought the potential to have the greatest impact in the lives of the patients under my care.”

Throughout his career, Dr. Skapek has mentored many young clinicians and researchers. “I believe that helping to educate the next generation of doctors who care for children with cancer and blood disease is an important part in the role that I play in this field,” he said.

In addition to his work at Children’s Health and UT Southwestern, Dr. Skapek serves on the Executive Committee and the Scientific Council of the Children’s Oncology Group, the world’s largest organization devoted exclusively to childhood and adolescent cancer research. He is also a member of the Cancer Prevention and Research Institute of Texas’ advisory committee on childhood cancer, and he holds the Distinguished Chair in Pediatric Oncology Research at UT Southwestern.

 

Education and Training

Education and Training

Medical School

Duke University (1988)

Residency

Wilford Hall Medical Center/CM (1991), Pediatrics

Fellowship

Harvard Medical School (1994), Biological Chem/Molec Pharmacy
Dana-Farber Cancer Institute (1994), Pediatric Hematology/Oncology
Research & Publications

Research & Publications

Research Interests

  • Elucidating molecular mechanisms for Arf-dependent regulation of vascular involution during eye development and tumor angiogenesis.
  • Studying the molecular basis for how persistent expression of cyclin D1 in mouse photoreceptors and pinealocytes disrupts normal eye development and leads to tumor formation as a novel model for retinoblastoma and pineoblastoma.
  • Treatment of children with aggressive fibromatosis using minimally-toxic therapy.
  • Understanding molecular and genetic mechanisms for coordinating the initiation of differentiation with cell proliferation arrest in skeletal myoblasts and determining whether the manipulation of these programs alters the biology of rhabdomyosarcoma-derived cells.

Selected Publications

  • p18Ink4cand p53 act as tumor suppressors in Cyclin D1-driven primitive neuroectodermal tumor., Saab R, Rodriguez-Galindo C, Matmati K, Rehg J, Baumer SH, Khoury JD, Billups C, Neale G, Helton KJ, Skapek SX. Cancer Research 2009 9 440-8
  • Expression of the Arf tumor suppressor gene is controlled by Tgf2 during development, Anderson-Freeman NE, Zheng Y, McCalla-Martin AC, Zheng Y, Treanor LM, Zhao YD, Garfin PM, He TC, Mary MN, Thornton JD, Anderson C, Gibbons M, Saab R, Baumer SH, Cunningham J, and Skapek SX Development 2009 136 2081-2089
  • Arf-dependent regulation of PDGF signaling in perivascular cells in the developing eye, Silva RLA, Martin AC, Thornton JD, Rehg JE, Berwistle D, Zindy F, and Skapek SX The EMBO Journal 2005 24 2803-2814
  • The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development, McKeller RN, Fowler JL, Cunningham JJ, Warner NW, Smeyne RJ, Zindy F, and Skapek SX Proceedings of the National Academy of Science 2002 99 3848-3853
  • Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase, Skapek SX, Rhee J, Spicer DB, Lassar AB Science 1995 267 1022-1024

Professional Activities

Professional Activities

Professional Associations and Affiliations

  • American Association for Cancer Research
  • American Society of Pediatric Hematology/Oncology
  • Association for Research in Vision and Ophthalmology
  • Intergroup Rhabdomyosarcoma Study Group
  • Children’s Oncology Group

Awards & Honors

Awards & Honors

  • American Cancer Society - Research Scholar Award (2004)
  • G and P Foundation for Cancer Research - Medical Research Award (1999)
  • NIH - Clinical Investigator Development Award (K08) (1994)
  • United States Air Force - Achievement Medal (1992)